• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alterity Therapeutics Limited

    4/28/25 8:01:50 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHE alert in real time by email
    6-K 1 ea0239687-6k_alterity.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-163

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2025

     

    Alterity Therapeutics Limited

    (Name of Registrant)

     

    Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

    This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

     

     

     

     

     

     

    ALTERITY THERAPEUTICS LIMITED

    (a development stage enterprise)

     

    The following exhibits are submitted:

     

    99.1 

    Alterity Phase 2 Presentation at MSA Symposium 2025

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Alterity Therapeutics Limited
         
      By: /s/ Geoffrey P. Kempler
        Geoffrey P. Kempler
        Chairman

     

    Date: April 28, 2025

     

     

    2

    Get the next $ATHE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHE

    DatePrice TargetRatingAnalyst
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    12/12/2024$8.00Buy
    Maxim Group
    8/20/2021$4.00Speculative Buy
    Benchmark
    More analyst ratings